These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27273032)

  • 1. Introduction.
    Gearry RB
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():23. PubMed ID: 27273032
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron and vitamin D deficiency in inflammatory bowel disease.
    Ghaly S
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():27-8. PubMed ID: 27273035
    [No Abstract]   [Full Text] [Related]  

  • 4. Organising infusions: Application administration and complications.
    Collins G
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():26. PubMed ID: 27273034
    [No Abstract]   [Full Text] [Related]  

  • 5. Ferric carboxymaltose approved for iron deficiency anemia.
    Thompson CA
    Am J Health Syst Pharm; 2013 Sep; 70(17):1458. PubMed ID: 23943169
    [No Abstract]   [Full Text] [Related]  

  • 6. [Iron deficiency therapy: focus is on the patient].
    Girrbach G
    MMW Fortschr Med; 2016 May; 158(10):88. PubMed ID: 27221451
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilar and innovator anti-Tumour Necrosis Factor (TNF) or lymphocyte trafficking blockade: Which one to select?
    Gearry RB
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():24-5. PubMed ID: 27273033
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous iron among cystic fibrosis patients.
    Hoo ZH; Wildman MJ
    J Cyst Fibros; 2012 Dec; 11(6):560-2. PubMed ID: 22717534
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Urato AC
    Obstet Gynecol; 2008 Sep; 112(3):703. PubMed ID: 18757678
    [No Abstract]   [Full Text] [Related]  

  • 10. [Not Available].
    Plate A
    Praxis (Bern 1994); 2016 Nov; 105(24):1443-1444. PubMed ID: 27911655
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical perspective: iron replacement therapy in chronic heart failure.
    Cowie MR; Lucas R
    Int J Clin Pract; 2011 Jun; 65(6):645-8. PubMed ID: 21564435
    [No Abstract]   [Full Text] [Related]  

  • 12. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 13. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic.
    Suárez Ferrer C; Pérez Robles T; Martín-Arranz MD
    Rev Esp Enferm Dig; 2021 Feb; 113(2):154. PubMed ID: 33371704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
    Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
    Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
    Barea Mendoza JA; Gredilla Zubiría I; González Olmedo J; Mateo Alvarez S
    Med Clin (Barc); 2014 Sep; 143(6):284-5. PubMed ID: 24461741
    [No Abstract]   [Full Text] [Related]  

  • 18. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research topic: Managing compassionate therapy-the role of the virtual clinic.
    Ward M
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():44-5. PubMed ID: 27273040
    [No Abstract]   [Full Text] [Related]  

  • 20. [Intravenous ferric carboxymaltose for the treatment of anemia in chronic renal disease].
    Merino JL; Bueno B; Campos MA; Amézquita Y
    Rev Clin Esp (Barc); 2014; 214(5):282-3. PubMed ID: 24582410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.